Aileron reports positive LTI-03 Phase 1b Cohort 1 IPF data; cash $12.0M

Rein Therapeutics, Inc.

7 of 8 biomarkers showed positive trend; 3 statistically significant: GAL-7 (p=0.0014), TSLP (p=0.0223), Col-1α1 (p=0.0489).
LTI-03 well-tolerated with no serious adverse events; solRAGE increased (p=0.1407), indicating type I epithelial cell health.
Cohort 1: 12 patients (9 active, 3 placebo), inhaled 2.5 mg BID; cohort 2 high-dose results expected Q3 2024.
Preliminary cash and cash equivalents ~$12.0M as of March 31, 2024, unaudited.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.